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A B S T R A C T
Purpose
Empiric antibiotic monotherapy is considered the standard of treatment for febrile neutropenic
patients with cancer, but this approach may be inadequate because of the increasing prevalence
of infections caused by multidrug resistant (MDR) bacteria.
Patients and Methods
In this multicenter, open-label, randomized, superiority trial, adult, febrile, high-risk neutropenic
patients (FhrNPs) with hematologic malignancies were randomly assigned to receive piperacillin/
tazobactam (4.5 g intravenously every 8 hours) with or without tigecycline (50 mg intravenously
every 12 hours; loading dose 100 mg). The primary end point was resolution of febrile episode
without modifications of the initial allocated treatment.
Results
Three hundred ninety FhrNPs were enrolled (combination/monotherapy, 187/203) and were
included in the intention-to-treat analysis (ITTA). The ITTA revealed a successful outcome in 67.9%
v 44.3% of patients who had received combination therapy and monotherapy, respectively
(127/187 v 90/203; absolute difference in risk (adr), 23.6%; 95% CI, 14% to 33%; P  .001). The
combination regimen proved better than monotherapy in bacteremias (adr, 32.8%; 95% CI, 19%
to 46%; P .001) and in clinically documented infections (adr, 36%; 95% CI, 9% to 64%; P .01).
Mortality and number of adverse effects were limited and similar in the two groups.
Conclusion
The combination of piperacillin/tazobactam and tigecycline is safe, well tolerated, and more
effective than piperacillin/tazobactam alone in febrile, high-risk, neutropenic hematologic patients
with cancer. In epidemiologic settings characterized by a high prevalence of infections because of
MDR microorganisms, this combination could be considered as one of the first-line empiric
antibiotic therapies.
J Clin Oncol 32. © 2014 by American Society of Clinical Oncology
INTRODUCTION
Patients with cancer who become granulocytopenic
as a result of intensive myelosuppressive chemother-
apy are at high risk of developing infections,1 which
may be lethal if empiric antibiotic treatment is not
promptly instituted. Nowadays, single-agent em-
piric antibacterial therapy may be considered the
standard of treatment.1-3 Over the past 30 years,
there has been a continuous change in the epidemi-
ology of bacterial infections in neutropenic patients
with cancer. Although Gram-positive cocci still rep-
resent the source of over 60% of bacteremias,4-6 a
new emergence of gram negatives has occurred, and
the diffusion of multidrug resistant (MDR) micro-
organisms has been observed.6-11 These new epide-
miologic settings in neutropenic patients with
cancer may be responsible for the inadequacy of the
commonly used empiric monotherapy regimens,12,13
which has led to an increased mortality.14,15 New anti-
Gram-positive drugs are currently available, but there
are only a few therapeutic options for MDR Gram-
negative infections. Tigecycline, the first in a new
class of glycylcyclines, is characterized by a broad
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antibacterial spectrum that covers the majority of MDR Gram-
positive and Gram-negative strains, with the exclusion of Pseudomo-
nas aeruginosa and Proteeae.16-21 Few clinical data on the safety and
effectiveness of tigecycline in neutropenic patients with cancer are
available.22 To investigate the possible benefits resulting from the
combination of this drug with the currently used monotherapy regi-
mens, we have conducted a large, controlled randomized clinical trial
by using piperacillin/tazobactam with or without tigecycline as empir-
ical antibiotic therapy in febrile neutropenic adult patients with hema-
tologic malignancies.
PATIENTS AND METHODS
Study Design and Participants
The study was a prospective, multicenter, unblinded, randomized, con-
trolled, superiority trial planned, conducted, and analyzed by the Gruppo
Italiano Malattie Ematologiche dell’Adulto Infection Program. It was regis-
tered in the EU Clinical Trials Database and approved by the ethics committee
at each participating center. The study was conducted between May 3, 2008,
and November 4, 2010, at 28 centers in Italy. Written informed consent was
obtained from each patient.
Consecutive adult patients with hematologic malignancies undergoing
intensive chemotherapy or conditioning regimens for autologous hematopoi-
etic stem-cell transplantation were eligible to be randomly assigned if they had
fever ( 38.5°C on one occasion or 38°C on two or more occasions within
12 hours), chemotherapy-induced neutropenia (absolute neutrophils
count 1,000 per cubic millimeter anticipated to decrease to fewer than 500
cells per cubic millimeter within 24 to 48 hours), and a presumed infection (ie,
fever not likely to be due to a noninfectious cause such as drug or blood
product administration). Patients were enrolled only once in the study. Pa-
tients were excluded if they had received any intravenous antibiotics during the
preceding 96 hours. Additional exclusion criteria are provided in the Appendix
(online only). Quinolones prophylaxis was discontinued at randomization.
Trial Objectives
The primary objective of the study was to show superiority in the rates of
successful response (defined as resolution of fever and clinical signs of infec-
tion and eradication of the infecting microorganisms, without modifications
of the initial allocated treatment) of the combination over the monotherapy
regimen. A response was defined as a failure if the patient died as a result of the
primary infection; if bacteremia persisted beyond the first 24 hours of therapy;
if a breakthrough bacteremia occurred; if the isolated pathogen was resistant to
the assigned antibiotics; if no response was seen after at least 72 hours of
therapy; if shock or acute respiratory distress syndrome or disseminated intra-
vascular coagulation or multiple organ failure was observed; if infection re-
lapsed within 7 days of treatment discontinuation; and if a toxicity attributed
to protocol antibiotics that required the interruption of treatment occurred.
Secondary end points were safety and tolerability. Survival at day 30 was
also evaluated.
Clinical and Microbiologic Assessment, Follow-Up
Details on baseline and follow-up assessments are provided in the Ap-
pendix. Patients were evaluated for response at day 4 after empirical therapy
initiation (early evaluation) and at the completion of the trial (overall evalua-
tion). Standardized efforts to evaluate persistent or relapsing fever were made.
Infections were classified according to the definitions of the European Orga-
nization for Research and Treatment of Cancer.23
Randomly assigned
(N = 390)
Assigned to combination regimen
(n = 187)*
Not eligible (n = 1)Not eligible
Treated
   Had leukemia
   Had lymphoma or
     other hematologic
     malignancies
(n = 186)
(n = 148)
(n = 38)
Treated
   Had leukemia
   Had lymphoma or
     other hematologic
     malignancies
(n = 202)
(n = 158)
(n = 44)
(n = 1)
Assigned to monotherapy
(n = 203)
Protocol violations
Early discontinuation
   of therapy
Fever not a result of 
   infection
Nonbacterial infection
(n = 4)
(n = 2)
(n = 1)
(n = 5)
Included in assessment of response
   Had leukemia
   Had lymphoma or other hematologic
     malignancies
(n = 174)
(n = 138)
(n = 36)
Included in the per-protocol analysis (n = 174) Included in the per-protocol analysis (n = 190)
Included in assessment of response
   Had leukemia
   Had lymphoma or other hematologic
     malignancies
(n = 190)
(n = 148)
(n = 42)
Protocol violations
Early discontinuation
   of therapy
Nonbacterial infection
Treatment interruption
   for unknown reasons
(n = 4)
(n = 2)
(n = 5)
(n = 1)
Fig 1. Enrollment and outcome. (*) The
trial enrollment was stopped shortly be-
fore reaching the planned number (190) in
this arm of the study because of impend-
ing expiry of the study insurance contract.
However, after having consulted the cen-
tral ethical committee, considering the
large and conservative anticipated rate of
not evaluability assumed in the sample
size calculation, the data review commit-
tee was confident that an adequate num-
ber of evaluable patients would have been
reached in each group of treatment, as it
actually occurred.
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Isolates identification and their susceptibility to antibiotics were evalu-
ated at each participating center according to the Clinical and Laboratory
Standards Institute guidelines.24 The growth of coagulase-negative staphylo-
cocci (CNS) was considered as bacteremia when two or more blood cultures,
drawn in separate occasions within 24 hours, yielded the same microorganism.
Extended spectrum beta-lactamase production in Enterobacteriaceae was
routinely carried out in three large centers. The minimum inhibitory concen-
tration (MIC) for tigecycline was determined by using Etest (AB-BioMe´rieux,
Solna, Sweden), and the MIC breakpoints for susceptibility issued by the
European Committee on Antimicrobial Susceptibility Testing ( 1 mg/L)
were used.25
Study Drug Treatment
At the onset of fever, patients were randomly assigned to receive pipera-
cillin/tazobactam (4.5 g intravenously every 8 hours) with or without tigecy-
cline (50 mg intravenously every 12 hours, loading dose of 100 mg) as empiric
therapy. Antibiotic treatment was continued until success or failure was de-
cided. The assigned therapy could be modified before day 4 only in the case of
a worsening of the patient’s clinical condition or if the isolated pathogen was
resistant to the assigned antibiotics, otherwise the modification was considered
a protocol violation.
Randomization and Statistical Analysis
Patients were centrally randomly assigned by using an automated com-
puter randomization procedure. The randomization list was created by using
a computer random generator program (Epistat, version 2) and was stratified
by center and underlying disease with a 1:1 allocation by using a block size of
eight. Participating centers were not aware of block size (Appendix).
According to our previous study,12 we assumed that a favorable response
would occur in approximately 50% of patients empirically treated with a
piperacillin/tazobactam monotherapy regimen. We estimated that at least 340
patients (170 in each group) would be needed to detect an absolute difference
of at least 15% between monotherapy and the combination regimen, with a
statistical power of 80% and a 5% significance level. Anticipating a 10%
nonevaluability rate, we planned to include at least 380 patients (190 in each
group) in the trial.
All case report forms were centrally reviewed by the data review commit-
tee and entered into the computer system blinded for the assigned regimen.
Statistical analyses were carried out at the Gruppo Italiano Malattie Emato-
logiche dell’Adulto Infection Program Data Center with the use of the SPSS
software package (SPSS, Chicago, IL) and were made in a blinded fashion with
respect to the assigned treatment. An analysis that included all eligible patients
was deemed according to the intention to treat by considering that treatment
was considered as failed in patients in whom response could not be assessed
because they were lost to follow-up. A per-protocol analysis that included all
assessable patients was conducted. Efficacy with respect to the primary and
secondary end points was expressed as the absolute difference in rates between
treatment groups (combination minus monotherapy regimen). The 95% CI
for the difference between proportions was given. The2 test with a correction
for continuity or Fisher’s exact test for small samples when necessary was used
to compare proportions. The Wilcoxon rank sum test was used to compare
continuous variables. A backward stepwise logistic regression model was used
to assess the relative importance of the various prognostic factors assessable at
the time of randomization.
RESULTS
A total of 390 febrile neutropenic hematologic patients with cancer
were enrolled: 187 assigned to receive intravenous piperacillin/
tazobactam plus tigecycline; 203 intravenous piperacillin/tazobactam.
The enrolment and outcome are shown in Figure 1. The characteris-
tics of patients included onto the study are provided in Table 1.
Response to Therapy
The rates and the absolute differences in the risk (adr) of primary
and secondary end points are shown in Figure 2. An intention-to-treat
analysis performed on the 390 eligible patients revealed that a success-
ful outcome was obtained in 67.9% of patients in the combination
group, compared with 44.3% of patients in the monotherapy group
(P .001).
A per-protocol analysis of patients whose response to the
assigned treatment could be assessed yielded similar results. The
response rate of microbiologically documented infections was sig-
nificantly higher in the combination group than in the mono-
therapy treated patients (61.4% v 28.1%; P .001).
Overall, 97.8% (180 of 184) of the microbiologically documented
infections were bacteremias (Fig 2). The distribution of bacteremias,
as well as the type of isolated pathogens, was similar in both treatment
groups, with CNS andEscherichia colibeing the most frequent isolates.
Table 1. Demographics and Clinical Characteristics of the 390 Patients Who
Entered Onto the Study
Characteristic
Pip/Tazo 
Tigecycline Pip/Tazo
No. % No. %
Patients 187 203
Sex
Male 104 102
Female 83 101
Age
Mean 54 53
Range 18-76 21-76
Underlying cancer
Acute leukemia 146 78 158 77.8
Lymphoma 30 16 28 13.8
Other hematologic malignancies 11 6 17 8.4
Chemotherapy
Remission induction/reinduction 110 58.8 117 57.6
Remission consolidation 36 19.2 41 20.2
Autologous stem-cell transplantation 28 15 36 17.7
Other 13 7 9 4.5
Use of growth factors 30 16 34 16.7
Oral antibacterial prophylaxis before
randomization
175 93.6 194 95.6
Antifungal prophylaxis 140 74.9 170 83.7
Antiviral prophylaxis 64 34.2 79 38.9
Intravenous catheter in situ 133 71.1 147 72.4
Protective environment 119 63.6 131 64.5
Single room 62 69
Reverse isolation 2 2
Laminar air flow room 37 43
Other 18 17
Duration of granulocytopenia, days
(neutrophils/mL)
 1,000
Mean 22 20
Range 1-142 1-61
Median 18 17
 500
Mean 11 12
Range 1-50 1-61
Median 10 10
Neutrophil count at entry ( 100
neutrophils/mL) 159 85 174 85.7
Abbreviation: Pip/Tazo, piperacillin/tazobactam.
Specific infection control measures for the prevention of carbapenem-
resistant strains spread were not routinely instituted.
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CNS blood isolates were methicillin-resistant in 79.5% of cases. The
prevalence of ESBL-producing strains documented by the three cen-
ters that routinely performed the screening and considered as repre-
sentative sample accounted for 30% of Enterobacteriaceae.
The success rate of patients with bacteremia treated with the
combination was 60.5%, compared with 27.7% of those treated with
monotherapy (P .001). Significantly higher success rates were ob-
served in patients with CNS and E coli bacteremia (Fig 2).
The reasons for failure are shown in Table 2. Failure because of an
isolate resistant to the initial allocated regimen occurred in eight of 174
patients treated with combination therapy (4.6%) compared with 27
of 190 patients treated with monotherapy (14.2%) (adr,0.09; 95%
CI, 0.15 to 0.03; P  .001). Susceptibilities of single agents and
polymicrobial bacteremias isolates are shown in Table 3. Resistant
pathogens were equally distributed in the two treatment groups. No
differences were detected in the number of days to defervescence that
were two (median, range 1 to 10) and three (median, range 1 to 17) in
patients treated with combination therapy and monotherapy, respec-
tively. The time to failure values were similar in both groups with a
median number of days to failure of 4 (range, 1 to 13 for combination
therapy and 1 to 17 for monotherapy).
Modification of the Allocated Antibiotic Regimen
Data on antibiotics prescribed as second-line treatment were avail-
able for 91% of cases of failure. A carbapenem (alone or in combination)
replaced the first-line regimen in 72.8% (99 of 136) of failed cases, but
overall 27.1% (99 of 364) of the assessable population received a
carbapenem. The use of an antipseudomonal cephalosporin or a
All treated patients
Group and Event
Combination
No. % No. %
Monotherapy
95% CI
Absolute 
Difference
in Risk
Absolute Difference
in Risk (95% CI)
Death
Death resulting from infective cause
AEs
Withdrawal due to AEs
Clinically documented
infection
Fever of unknown
origin
Documented infections
    Pneumonia
    Central venous catheter
    Abdominal
    SSTI†
Monotherapy better Combination better
9.02.01.01.0-2.0- 0.80.70.60.50.40.3
0
Microbiologically documented
infections
Bacteremia
    Gram positive
       Staphylococcus aureus
       Coagulase-negative Staph*
       Enterococci 
       Streptoocci
       Other gram positive
    Gram negative
       Escherichia coli
       Pseudomonas spp
       Klebsiella spp
       Other gram negative
    Polymicrobial
Febrile episode resolution
-0.04 to 0.06
-0.04 to 0.05
-0.04 to 0.04
-0.03 to 0.01
0.09 to 0.64
-0.01 to 0.25
0.21 to 0.46
-0.26 to 0.69
-0.13 to 0.67
-0.12 to 0.79
0.59 to 1.12
 
0.19 to 0.46
0.19 to 0.46
0.17 to 0.56
0.22 to 0.69
-0.50 to 0.83
-0.23 to 0.85
0.09 to 0.90
0.05 to 0.51
0.16 to 0.72
-0.55 to 0.15
0.01 to 0.99
-0.89 to 0.55
-0.10 to 0.58
0.15 to 0.34
 0.01
0.004
0.0001
-0.008
0.36
0.11
0.34
0.21
0.27
0.33
0.85
 
0.33
0.32
0.36
0.45
0.16
0.31
0.50
0.28
0.44
-0.20
0.50
-0.16
0.24
0.25 
7.3
5.4
6.4
2.4
47.4
72.0
31.3
50.0
35.3
16.7
14.3
 
28.1
27.7
34.8
31.0
50.0
40.0
0.0
24.1
23.5
20.0
0.0
50.0
15.8
47.4
15 of 203
11 of 203
13 of 203
5 of 203
9 of 19
54 of 75
36 of 115
4 of 8
6 of 17
1 of 6
1 of 7
 
27 of 96
26 of 94
16 of 46
2 of 4
9 of 29
3 of 6
2 of 5
0 of 2
7 of 29
4 of 17
1 of 5
0 of 3
2 of 4
3 of 19
50.0
90 of 190
8.5
5.8
6.4
1.6
84.2
83.6
65.4
71.4
62.5
50.0
100
 
61.4
60.5
71.4
 
76.9
66.7
71.4
50.0
52.9
68.2
0.0
50.0
33.3
40.0
72.4
16 of 187
11 of 187
12 of 187
3 of 187
16 of 19
56 of 67
70 of 107
5 of 7
5 of 8
4 of 8
6 of 6
 
54 of 88
52 of 86
30 of 42
20 of 26
2 of 3 
5 of 7
3 of 6
18 of 34
15 of 22
0 of 5
2 of 4
1 of 3
4 of 10
126 of 174
All assessable patients
Febrile episode resolution 127 of 187 67.9 90 of 203 44.3 0.23 0.14 to 0.33
Fig 2. Rates and absolute differences in the risk of primary and secondary end points. (*) Overall, data on methicillin-resistance (MR) were available for 44 of 55 strains
(80%); 35 of 44 (79.5%) coagulase-negative Staphylococcus were MR. (†) Severe skin and soft tissue infection (SSTI). AE, adverse event.
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carbapenem was significantly higher in the monotherapy than in the
combination regimen (67 of 183, 36.6% v 37 of 169, 21.9%; adr, 0.14;
95% CI, 0.05 to 0.24; P .01). Similarly an anti-Gram-positive agent
was used as second-line treatment in 69 of 183 (37.7%) and 25 of 169
(14.8%) of cases, respectively, in the monotherapy and in the combi-
nation regimen (adr, 0.23; 95% CI, 0.14 to 0.31; P .01).
Tigecycline was used as second-line therapy in 34 of 100 patients
who failed on piperacillin/tazobactam monotherapy. In the 26 assess-
able cases, the success rate was 69% in 16 bacteremias and in three
clinically documented infections, and it was 86% in seven cases of
unexplained fever.
Multivariable Analysis
To estimate predictive factors that could influence the failure of
empiric therapy, data from all assessable patients were fitted within a
multivariable logistic regression model. Factors included in the model
were as follows: antibiotic regimen, sex, age, performance status
(WHO five-degree scale), underlying disease, neutrophil count at
onset of fever, and duration of neutropenia. Although the duration of
neutropenia  10 days, acute leukemia, and monotherapy were sig-
nificant factors for failure at the univariable level, only the last two
resulted independent risk factors at the multivariable level (Table 4).
Mortality
The mortality rates and causes of death were equally distributed
between the two treatment groups (Table 5). Overall, 16 patients
(8.5%) who were in the combination group died, compared with 15
(7.3%) in the monotherapy group (P .4). Eleven patients died as a
result of infectious causes in both treatment groups. Overall, 16 deaths
were bacteremia related, and in 11 cases (68.7%) a Gram-negative
microorganism was involved.
The bacteremia-related mortality rates were similar, being 4% in
both regimens (P .4). Early death (within 72 hours from the start of
the empiric therapy) in bacteremic febrile episodes occurred in one
of 187 patients (0.5%) treated with combination regimen and in four
of 203 patients (2%) treated with monotherapy (P  .2; estimated
relative risk, 0.27; 95% CI, 0.03 to 2.41), and a Gram-negative strain
was involved in four of five cases.
Adverse Events
Three hundred ninety patients were assessable for adverse events.
The overall incidence of adverse events was 6.4% in both treatment
groups (12 of 187 in the combination and 13 of 203 in the mono-
therapy group). Nausea, vomiting, and diarrhea occurred in seven
patients (3.7%) treated with tigecycline. Toxicities resulted in the
discontinuation of treatment in three patients undergoing the combi-
nation and in five receiving monotherapy.
Table 3. Pip/Tazo, Tigecycline, and Levofloxacin Resistance in Single-Agent and Polymicrobial Bacteremias
Organism
Pip/Tazo Tigecyclin Levofloxacin
No. Resistant/Total No.
Available for Analysis %
No. Resistant/Total No.
Available for Analysis %
No. Resistant/Total No.
Available for Analysis %
Escherichia coli 15/46 33 3/44 7 39/40 97
Pseudomonas spp 5/9 55 9/9 100 7/8 87
Klebsiella spp 4/11 36 1/10 10 10/10 100
Other Gram negative 2/5 40 0/3 0 2/4 50
Total gram-negative organisms 26/71 37 13/66 20 58/62 94
Staphylococcus aureus 3/7 43 1/7 14 2/6 33
MRSA 3/3 100 1/3 33 2/2 100
MSSA 0/4 0 0/4 0 0/4 0
Coagulase-negative Staphylococcus 58/62 94 4/58 7 51/61 84
MRCNS 53/53 100 3/43 7 37/45 82
MSCNS 5/9 55 1/15 7 14/16 87
Enterococcus spp 7/11 64 2/11 18 6/9 67
Streptococcus spp 1/10 10 0/8 0 10/12 83
Other Gram positive 2/4 50 2/5 40 3/3 100
Total gram-positive organisms 71/94 75 9/89 10 72/91 79
Abbreviations: MRCNS, methicillin-resistant coagulase-negative Staphylococcus; MRSA, methicillin-resistant Staphylococcus aureus; MSCNS, methicillin-
susceptible coaulase-negative Staphylococcus; MSSA, methicillin-susceptible Staphylococcus aureus; pip/tazo, piperacillin/tazobactam.
Table 2. Reasons for Failure
Reasons for Failure
Pip/Tazo 
Tigecycline,
174
Assessable
Patients
Total
Failures
(n  48)
Pip/Tazo,
190
Assessable
Patients
Total
Failures
(n  100)
No. % No. %
Subjective 21 43.8 41 41
Persistent fever or relapsing fever 15 31.3 29 29
Progression of primary infection 6 12.5 12 12
Objective 27 56.2 59 59
Persistent bacteremia 6 12.5 10 10
Resistant pathogen 5 10.4 17 17
Breakthrough bacteremia 3 6.2 9 9
Shock, ARDS, multiorgan failure 2 4.3 4 4
Withdrawal because of toxicity 3 6.2 5 5
Death as a result of the primary infection 3 6.2 1 1
Two or more reasons 5 10.4 13 13
Abbreviations: ARDS, acute respiratory distress syndrome; Pip/Tazo,
piperacillin/tazobactam.
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DISCUSSION
The increase of relative proportion of bacteremias caused by gram
negatives6-8 and, at the same time the emergence of MDR
microorganisms,9-11 may be responsible for the inadequacy of mono-
therapy regimens, as well as of the classical-lactam and aminoglyco-
side combination for the empiric treatment of febrile neutropenia in
patients with cancer.2,11-13 In this context, our study addresses two
important issues: whether an association of antibiotics is better than
monotherapy and whether tigecycline in combination can be used as
empiric antibiotic therapy.
To our knowledge, this is the first multicenter, randomized,
controlled, prospective trial powered to demonstrate that the combi-
nation of piperacillin/tazobactam with tigecycline is more effective
than piperacillin/tazobactam alone for the empiric treatment of fever
in persistently granulocytopenic patients with cancer. Combination
regimen was associated with a significantly higher success rate com-
pared with monotherapy in patients with bacteremia, as well as in
patients with clinically documented infections. The use of the same
antipseudomonal drug in the two arms of treatment and the uniform
protocol guidelines for therapeutic decisions enabled us to attribute
the differences in clinical responses exclusively to tigecycline.
Our study was open label. Unfortunately, the high cost of
double dummy preparations and the difficulties to guarantee the
use of an adequate masking technique in each participating center
(because of the easily recognizable orange color of tigecycline
solution), made the blinded design unaffordable for a spontaneous
no-profit study.
Our methodology was aimed at reducing the possibility of bias in
the interpretation of the results. Moreover, all the data recorded in the
case report forms were entered into the computer system and assessed
blinded for the assigned regimen by the data review committee.
In any case, the investigators’ judgment does not seem to have
been influenced by the unblinded design. In our study, both persistent
or relapsing fever and progression of infection were considered and
analyzed as reasons for failure burdened by subjectivity compared
with other more objective and verifiable reasons. As shown in Table 3,
Table 5. Mortality Rates in the Treated Population
Variable
Pip/Tazo 
Tigecycline
(N  187)
Pip/Tazo
(N  203)
Absolute Difference in Risk
(95% CI)
No. % No. % P
Death 16 8.5 15 7.3 0.01 (0.04 to 0.06) 0.4
Death because of infection 11 5.8 11 5.4 0.004 (0.04 to 0.05) 0.5
Microbiologically documented infection with bacteremia 8 4.2 8 3.9 0.003 (0.03 to 0.04) 0.4
Single gram-negative isolate 5 2.7 3 1.5
Escherichia coli 2 2
Klebsiella spp 1 —
Pseudomonas spp 2 1
Single gram-positive isolate 2 1 2 1
Enterococcus spp 1 1
Streptococcus spp 1 —
Methicillin-resistant coagulase-negative Staphylococcus — 1
Polymicrobial 1 0.5 3 1.4
E coli plus gram-positive organism 1 2
Gram-positive organisms only — 1
Clinically documented infection 1 0.5 1 0.5
Fever of unexplained origin — 1
Death because of fungal infection 2 1 1 0.5
Death from noninfectious causes 5 2.7 4 1.9 0.007 (0.02 to 0.03) 0.4
Bacteremia-related early death (death occurring within 72
hours from the start of empiric therapy) 1 0.5 4 2 0.01 (0.03 to 0.007) 0.2
Single agent bacteremia† 1 3
Polymicrobial bacteremia 0 1‡
Abbreviation: pip/tazo, piperacillin/tazobactam.
Deaths occurred within the 7-day period after antibiotic treatment (including modification of the assigned regimen) discontinuation.
†Combination therapy: one E coli; Monotherapy: two E coli and one coagulase-negative Staphylococcus.
‡E coli plus Enterococcus spp.
Table 4. Multivariable Backward, Logistic Regression Model: Factors
Associated With the Failure of Empiric Antibiotic Therapy
Variables Category OR 95% CI P
Antibiotic regimen Monotherapy 2.86 1.59 to 4.12  .001
Combination 1
Underlying
disease
Acute leukemia 2.54 1.18 to 3.90 .002
Other hematologic
malignancies
1
NOTE. Others factors included in the model but not associated with the
failure of empiric antibiotic therapy were as follows: Sex: male v female; age
(years):  65 v  65; performance status (WHO five points scale)  2 v  2;
neutrophil count at onset of fever:  100/mL v  100/mL; and duration of
neutropenia (days):  10 v  10.
Abbreviation: OR, odds ratio.
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each reason for failure was equally distributed between the two treat-
ment groups, and an objective and verifiable reason for failure repre-
sented approximately 60% of the total causes of failure in both
treatment arms. Noteworthy, even if all the cases that failed because of
a possible investigator’s subjective judgment were reclassified as suc-
cesses, the success rate of the combination was still higher than that of
monotherapy (147 of 174 v 131 of 190; adr, 15%; 95% CI, 7% to 24%;
P .001).
Tigecycline in combination with an antipseudomonal agent
was effective regardless of the site of the infection. A substantial
better response of the combination regimen was documented in
bacteremias, in particular those caused by staphylococci and E coli.
Because tigecycline achieves modest plasma concentrations, con-
cerns were raised about its efficacy in the treatment of bacteremias
and infections with organisms with a higher MIC.26-30 However,
no studies have been designed to evaluate the efficacy of tigecycline
in bacteremias, although Chemaly22 observed a good clinical re-
sponse by using tigecycline for refractory bacteremias in patients
with cancer.
In our study, the results of the combination regimen in bactere-
mias might have been influenced by an overall better in vitro activity of
tigecycline against blood isolates compared with that of piperacillin/
tazobactam and also by the low incidence of bacteremias because of P
aeruginosa, not covered by the tigecycline spectrum of activity. Note-
worthy, in the combination arm, more than 30% of pathogens in-
volved in single agent bacteremias were susceptible only to tigecycline,
whereas tigecycline was the only active drug against the involved
microorganisms in 60% of polymicrobial bacteremias. In patients
with cancer, the reported rates of ESBL producer among E coli
causing bacteremias account for up to 40%.14,15,31,32 At the same
time, mortality and the delay of effective therapy have been associ-
ated with ESBL production in Enterobacteriaceae bactere-
mia.15,31,32 The results of our study seems to indicate that in febrile,
high-risk neutropenic patients (FhrNPs) the addition of tigecy-
cline, active also against ESBL producers, could improve the ade-
quacy of initial empiric monotherapy, and they also suggest that
tigecycline in combination may contribute to reduce the overuse of
carbapenems (overall, in our study, only the 27% of assessable
population received a carbapenem) and anti-Gram-positive
agents, as strongly recommended for the prevention of emergence
of resistance.33,34
This study was not powered to document an effect of the
tigecycline combination in the reduction of mortality that in neu-
tropenic patients with cancer may be also influenced by factors
other than the empiric antibiotic therapy. The overall mortality
rate evaluated at the end of the febrile episode was limited and
similar in the two treatment groups. However, in patients receiving
the combination therapy, we observed that a lower number of
bacteremia-related early deaths occurred under the assigned anti-
biotic regimen (a Gram-negative was involved in four of five cases).
Even if the difference was not statistically significant, it should be
noted that in the combination arm only 12% of deaths because of
bacteremia occurred within the first 72 hours from the start of
empiric antibiotic therapy, compared with 50% in the mono-
therapy arm. This result is in line with studies revealing a better
outcome and a higher overall survival rate in patients receiving
initial adequate antibiotic therapy.10,14,31,32 The study confirms
that in FhrNPs, tigecycline is safe and well tolerated.
In conclusion, the results of our study support the view35 that
a broad initial empirical combination regimen should be reserved
to FhrNPs at high risk of developing infections because of
MDR pathogens.
Because the majority of our patients was affected by acute
leukemia, which was an independent factor for antibiotic treat-
ment failure, and they had received intensive chemotherapy, the
results of our study may not pertain to patients affected by other
types of cancer, undergoing less intensive chemotherapy, and not
receiving quinolones prophylaxis. We therefore believe that the
combination containing tigecycline should be used as empiric
therapy only for febrile neutropenic patients with acute leukemia
in epidemiologic settings characterized by a high rate of MDR
microorganisms, such as those observed in our study. The knowl-
edge of local epidemiology is needed to drive the empiric antibiotic
strategies together with a stringent enforcement of antibiotic stew-
ardship programs.
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GLOSSARY TERMS
febrile neutropenia: symptoms include fever and a decrease
in the number of neutrophils in the blood. A low neutrophil
count increases the risk of infection.
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Appendix
Inclusion and Exclusion Criteria
Consecutive adult patients with acute leukemia or lymphoma and other hematologic malignancies (undergoing conventional
intensive chemotherapy or conditioning regimens for autologous hematopoietic stem-cell transplantation) were eligible to be randomly
assigned if they had fever ( 38.5°C on one occasion or  38°C on two or more occasions within 12 hours), chemotherapy-induced
neutropenia (absolute neutrophils count 1,000 per cubic millimeter anticipated to decrease to fewer than 500 cells per cubic millimeter
within 24 to 48 hours), and a presumed infection (ie, fever not likely to be due to a noninfectious cause such as drug or blood product
administration). Patients were enrolled only once in the study and were hospitalized at the participating centers.
Patients were excluded from the trial if they had received any intravenous antibiotics during the preceding 96 hours, had a known
allergy to any of the protocol antibiotics, had renal failure requiring hemo- or peritoneal dialysis or a serum creatinine level greater than
25 mL/min, were pregnant, or had known human immunodeficiency virus infection.
Randomization Procedure
Patients were centrally randomly assigned by using an automated computerized randomization procedure. The randomization list
was created by using a computer random number generator program (Epistat, version 2) and was stratified by center and underlying
disease with a 1:1 allocation by using a block size of eight. Participating centers were not aware of block size.
Treatment assignment was carried out directly by the Gruppo Italiano Malattie Ematologiche dell’Adulto centralized randomization
system, using an Internet connection, a PC, and a modem. One set of envelopes was kept in each center to be used in case of computer
failure or connection problems. After the investigator had obtained the patient’s consent, he connected to the centralized randomization
system for the allocation consignment.
Baseline and Follow-Up Assessments
After randomization, the empiric antibiotic treatment was started immediately at onset of fever. Physical examinations, routine chest
x-rays, as well as a complete battery of laboratory tests, including urine culture and two sets of blood cultures (from different venipunctures
and, in the presence of a central venous catheter, from catheter and peripheral vein) were performed before initiating the study antibiotics.
Other cultures were performed as clinically indicated. After randomization, each patient was evaluated daily for adverse effects, and
detailed clinical assessments were made at baseline and daily thereafter while the patient was being treated, as well as on the last day of
treatment and 7 to 10 days after completion of therapy. Patients were evaluated for response as follows: at day 4 (between 72 and 96 hours)
after empirical therapy initiation (early evaluation) when the results of baseline microbiologic cultures were available, and at the
completion of the trial (overall evaluation). Antibiotic treatment was continued until success or failure was decided. The assigned therapy
could only be modified before the 72 to 96 hours in the case of a worsening of the patient’s clinical condition or in the case of an early
documentation of an infection caused by a resistant pathogen otherwise the treatment modification earlier than 72 to 96 hours was
considered a protocol violation.
The Gruppo Italiano Malattie Ematologiche dell’Adulto Infection Program Also Includes the Following
Investigators and Centers:
Mara Merluzzi (Universita` degli Studi di Perugia, Perugia), Elisabetta Agliani (Ospedale S. Maria della Misericordia, Perugia), Saveria
Capria (A. O. Policlinico Umberto I, Roma); Fabrizio Pane (A. O. Universitaria “Federico II,” Napoli); Lorella Melillo (Ospedale Casa
Sollievo della Sofferenza, IRCCS, San Giovanni Rotondo); Giuseppe Fioritoni (Ospedale Civile “Spirito Santo,” Pescara); Mario Delia
(Universita` di Bari, Bari), Raimonda Fjerza (A. O. Universitaria “Careggi,” Firenze); Monica Morselli (A. O. Universitaria Policlinico,
Modena); Licia Ottaviani (Policlinico Tor Vergata, Roma); Stefano Molica (A. O. “Pugliese Ciaccio,” Catanzaro); Salvatore Leotta
(Policlinico “Vittorio Emanuele,” Catania); Luca De Rosa (A. O. San Camillo Forlanini, Roma); and Chiara Cattaneo (Spedali Civili, Brescia).
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